In Brief: Ortec International
This article was originally published in The Gray Sheet
Executive Summary
Ortec International: "Successfully defends" U.S. patent on its Composite Cultured Skin biologically active skin replacement against a re-examination procedure initiated by competitor Organogenesis in February 1994, the firm reports. On Dec. 10, the U.S. patent office reissued Ortec's CCS patent "with modifications which do not substantially change the scope of the original patent," the company says. Ortec is conducting U.S. clinical trials at five centers to support a premarket approval application for the full-thickness skin replacement ("The Gray Sheet" April 29, I&W-7)...
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.